Skip to content
Screener

West Pharmaceutical Services WST Payments to Acquire Property, Plant, and Equipment

Payments to Acquire Property, Plant, and Equipment at other companies

Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
$4.17M+167%
Lifecore Biomedical, Inc. logo
Lifecore Biomedical, Inc.LFCR
$1.63M
AptarGroup logo
AptarGroupATR
Sonoco Products logo
Sonoco ProductsSON

Other financials

Income statement

See full
Revenue$872.3M+13.8%
Gross profit$329.2M+20.2%
Operating income$179.1M+16.5%
Net income$154.0M+16.8%
EPS (diluted)$2.15+18.1%

Balance sheet

See full
Cash & equivalents$435.8M-14.5%
Total debt$316.5M+2.7%
Total equity$3.0B+2.1%
Total assets$4.1B+3.1%

Cash flow

See full
Operating cash flow$124.0M-30.0%
CapEx$43.2M-42.6%
Free cash flow$80.8M-20.7%

Valuation

See full
Market cap$24.92B+44.2%
Enterprise value$24.8B+45.2%
P/E44.1×+8.7×
P/S7.5×+1.7×

Profitability

See full
Gross margin36.8%+1.5pp
Operating margin20.5%+0.8pp
Net margin17%+0.5pp
FCF margin13.1%+1.5pp

Returns & leverage

See full
Return on equity19.1%+1.4pp
Debt / equity0.1×0.0×
Current ratio2.8×0.0×

Where this comes from

Reported directly by West Pharmaceutical Services in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

The source filing: West Pharmaceutical Services’s 10-Q, filed July 23, 2026.

Filed
Jul 23, 2026, 4:15 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000105770-26-000099
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Changes in assets and liabilities(188.9)(4.0)
Net cash provided by operating activities213.9306.5
Cash flows from investing activities:
Capital expenditures(85.9)(146.5)
Net cash used in investing activities(85.9)(146.5)
Cash flows from financing activities:
Borrowings under revolving credit agreements50.0
Repayments under revolving credit agreements(50.0)

Item 1. FINANCIAL STATEMENTS (UNAUDITED)

FAQ

What is West Pharmaceutical Services's payments to acquire property, plant, and equipment?
West Pharmaceutical Services (WST) reported payments to acquire property, plant, and equipment of $43.2M in Q2 2026.
How has West Pharmaceutical Services's payments to acquire property, plant, and equipment changed year-over-year?
West Pharmaceutical Services's payments to acquire property, plant, and equipment decreased by 42.6% year-over-year, from $75.2M to $43.2M.
What is the long-term trend for West Pharmaceutical Services's payments to acquire property, plant, and equipment?
Over 4 years (2021 to 2025), West Pharmaceutical Services's payments to acquire property, plant, and equipment has grown at a 3.1% compound annual growth rate (CAGR), from $253.4M to $285.9M.

Ask your AI about West Pharmaceutical Services's payments to acquire property, plant, and equipment.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude